Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Total Liabilities (2016 - 2025)

Altimmune (ALT) has disclosed Total Liabilities for 16 consecutive years, with $55.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 248.38% to $55.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $55.0 million through Dec 2025, up 248.38% year-over-year, with the annual reading at $55.0 million for FY2025, 248.38% up from the prior year.
  • Total Liabilities for Q4 2025 was $55.0 million at Altimmune, up from $32.8 million in the prior quarter.
  • The five-year high for Total Liabilities was $55.0 million in Q4 2025, with the low at $14.5 million in Q3 2024.
  • Average Total Liabilities over 5 years is $21.3 million, with a median of $18.6 million recorded in 2021.
  • The sharpest move saw Total Liabilities tumbled 30.58% in 2021, then skyrocketed 248.38% in 2025.
  • Over 5 years, Total Liabilities stood at $19.7 million in 2021, then rose by 9.66% to $21.6 million in 2022, then fell by 23.55% to $16.5 million in 2023, then decreased by 4.49% to $15.8 million in 2024, then surged by 248.38% to $55.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $55.0 million, $32.8 million, and $29.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.